US equities
|
SPCX
$166.69
▲+4.86%
NVDA
$236.84
▲+1.24%
MU
$1,063.85
▼-1.03%
TSLA
$375.50
▲+1.32%
MSFT
$525.93
▲+1.62%
INTC
$116.92
▼-2.02%
SNDK
$1,718.00
▼-0.12%
META
$743.33
▲+2.09%
SPCX
$166.69
▲+4.86%
NVDA
$236.84
▲+1.24%
MU
$1,063.85
▼-1.03%
TSLA
$375.50
▲+1.32%
MSFT
$525.93
▲+1.62%
INTC
$116.92
▼-2.02%
SNDK
$1,718.00
▼-0.12%
META
$743.33
▲+2.09%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
17.14
-0.36 (-2.06%)
Delayed Quote
Updated: 10:44 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
36
37
Next >
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Looking At Sarepta Therapeutics's Recent Unusual Options Activity
↗
June 26, 2024
Via
Benzinga
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
↗
June 26, 2024
One company's negative results can increase scrutiny of another's work.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years
↗
June 24, 2024
Via
Benzinga
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
↗
June 24, 2024
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier.
Via
Investor's Business Daily
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
↗
June 24, 2024
Via
Benzinga
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
↗
June 23, 2024
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%).
Via
Benzinga
Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More
↗
June 21, 2024
Alphabet stock has more than doubled since February 2023 and it continues to outperform. It boasts a best-possible 99 Composite Rating.
Via
Investor's Business Daily
Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year
↗
June 21, 2024
Technology sector dominates growth stocks, boosted by strong earnings and investor confidence. Value stocks struggle due to less impressive performance and subdued earnings expectations. Growth...
Via
Benzinga
Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings
↗
June 21, 2024
Via
Benzinga
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 21, 2024
Via
Benzinga
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
↗
June 21, 2024
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.
Via
Benzinga
Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
↗
June 21, 2024
Wall Street is experiencing a subdued and low volatility trading day Friday, despite the session coinciding with the “triple witching” day, with over $5.1 trillion of notional options exposure...
Via
Benzinga
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
↗
June 21, 2024
FDA approves Sarepta's Elevidys for Duchenne muscular dystrophy patients with confirmed DMD gene mutation, aged 4+. Expanded label boosts revenue prospects for SRPT as payers and analysts show strong...
Via
Benzinga
Gold Down 1%; CarMax Shares Gain After Q1 Earnings
↗
June 21, 2024
Via
Benzinga
Sarepta Therapeutics Stock Soars on FDA Approval
June 21, 2024
Sarepta Therapeutics' expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market.
Via
MarketBeat
Why Is Ascent Solar (ASTI) Stock Up 11% Today?
↗
June 21, 2024
Ascent Solar stock is up on Friday with heavy trading of ASTI shares after the company announced a debt payoff to institutional investors.
Via
InvestorPlace
Why Is 36Kr (KRKR) Stock Up 17% Today?
↗
June 21, 2024
36Kr stock is up Friday after the content creation company announced a partnership with SenseTime that brings heavy trading of KRKR shares.
Via
InvestorPlace
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
↗
June 21, 2024
Via
Benzinga
Stock Market Weekly Review: Nvidia, AI Chip Plays Hit Resistance
↗
June 21, 2024
The Nasdaq and S&P 500 backed off highs. The Dow regained a key level.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Stocks
Pre-Market Movers - June 21, 2024
↗
June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers.
Via
Talk Markets
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost
↗
June 21, 2024
How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging.
Via
InvestorPlace
Apple To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
↗
June 21, 2024
Via
Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
↗
June 21, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 21, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
June 21, 2024
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
↗
June 21, 2024
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations.
Via
Benzinga
Wall Street Looks Set For Modestly Lower Start Ahead Of Key Data, Tech Stocks Muted In Premarket: Analyst Says 'Bearish Sentiment Has Become Understandably Quiet'
↗
June 21, 2024
Wall Street is on track for a lackluster open after the S&P 500’s back-to-back record performances in the first two sessions of the week. The major index futures were all uniformly lower in early...
Via
Benzinga
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
↗
June 20, 2024
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
June 20, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
36
37
Next >
